治療時代を超えた多発性硬化症の再発リスク因子
Evan Madill, Brian Healy1, Mariann Polgar-Turcsanyi2
1Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA Department of Neurology, Harvard Medical School, Boston, MA, USA.
Multiple sclerosis journal - experimental, translational and clinical
|December 25, 2025
まとめ
多発性硬化症(MS)における再発リスク因子は、初期と最近の治療時代の間で有意に変化しなかった。若年年齢と効果の低い治療法が主要な予測因子であり続けたが、個々のリスクは変動する。
科学分野:
- 神経学
- 臨床研究
- 疫学
背景:
- 多発性硬化症(MS)の再発活動は、年齢と性別によって影響される。
- MS再発リスク因子に対する進化する治療パラダイムの影響はよく理解されていない。
研究 の 目的:
- 臨床的に孤立した症候群または再発発症MS患者の臨床的再発の予測因子を評価すること。
- 異なる治療時代における再発リスク因子の比較。
主な方法:
- 臨床的に孤立した症候群または再発発症MSの成人2192人を対象とした後ろ向きコホート研究。
- 患者を「初期」(1997-2010)および「最近」(2010-2020)の治療時代に分類した。
- 多変量ロジスティック回帰により、初回受診後3年以内の再発予測因子を分析した。
主要な成果:
- 初期コホートでは、若年年齢、女性、再発寛解型疾患、過去の再発、およびプラットフォーム療法が再発を予測した。
- 最近のコホートでは、年齢、MSの家族歴、およびプラットフォーム療法が再発を予測した。
- モデルの精度は時代を通じて一貫していた。交互作用項は有意ではなかった。
結論:
- 多発性硬化症(MS)の再発予測因子は、治療時代を通じて実質的な違いを示さなかった。
- 若年年齢と効果の低い治療法が、初回受診時の有意なリスク因子として特定された。
- 個々の再発リスクは、有意な異質性を示した。
さらに関連する動画
関連する概念動画
Psychological and Sociocultural Causes of Schizophrenia
438
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
438
Factors Affecting Drug Response: Overview
2.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
224
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
224


